65.34

0.83% +0.54

Pre-market: 63.51 -1.83 -2.80%

Cytokinetics Inc (CYTK)

Overview News Price History Option Chain Why CYTK Down? Discussions Forecast Stock Split

Cytokinetics Inc stock is currently priced at $65.34, with a 24-hour trading volume of 635.98K. It has seen a +0.83% increased in the last 24 hours and a -8.17% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $64.71 pivot point. If it approaches the $65.51 resistance level, significant changes may occur.

Previous Close:

$64.80

Open:

$65

24h Volume:

635.98K

Market Cap:

$6.83B

Revenue:

$7.53M

Net Income/Loss:

$-526.24M

P/E Ratio:

-11.84

EPS:

-5.52

Net Cash Flow:

$-415.75M

1W Performance:

-3.27%

1M Performance:

-8.17%

6M Performance:

+101.60%

1Y Performance:

+75.93%

1D Range:

$64.50

$66.12

52W Range:

$25.98

$110.25

Cytokinetics Inc Stock (CYTK) Company Profile

Name

Cytokinetics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

650-624-3000

Address

280 East Grand Avenue, South San Francisco, CA

Employee

137

Twitter

@Cytokinetics

Next Earnings Date

2024-05-15

Latest SEC Filings

CYTK's Discussions on Twitter

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-24-24	Downgrade	UBS	Buy → Neutral
Jan-05-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-07-23	Initiated	B. Riley Securities	Buy
Aug-15-23	Initiated	SVB Securities	Outperform
Feb-17-23	Initiated	BofA Securities	Neutral
Dec-23-22	Reiterated	Needham	Buy
Dec-20-22	Initiated	Truist	Buy
Oct-11-22	Initiated	UBS	Buy
Jan-28-22	Initiated	Goldman	Buy
Dec-22-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	JP Morgan	Overweight
Oct-07-21	Initiated	Jefferies	Buy
Mar-12-21	Initiated	Wolfe Research	Outperform
Feb-18-21	Initiated	Barclays	Overweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-29-20	Initiated	Goldman	Neutral
Jul-10-20	Initiated	Raymond James	Strong Buy
May-05-20	Initiated	Mizuho	Buy
Apr-09-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-10-18	Resumed	Morgan Stanley	Equal-Weight
Nov-22-17	Reiterated	Morgan Stanley	Overweight
Nov-22-17	Downgrade	Needham	Strong Buy → Buy
Nov-21-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Initiated	Morgan Stanley	Overweight
Mar-08-17	Initiated	Rodman & Renshaw	Buy
Feb-06-17	Upgrade	Needham	Buy → Strong Buy
Dec-16-16	Initiated	Cantor Fitzgerald	Overweight
Jul-28-16	Reiterated	Needham	Buy
Nov-10-15	Reiterated	FBR Capital	Outperform
Nov-09-15	Reiterated	ROTH Capital	Buy
Jul-24-15	Reiterated	MLV & Co	Buy
Dec-31-14	Reiterated	ROTH Capital	Buy
Nov-04-14	Upgrade	MLV & Co	Hold → Buy
Apr-28-14	Reiterated	Needham	Buy

View All

Cytokinetics Inc Stock (CYTK) Latest News

Cytokinetics to Announce First Quarter Results on May 8, 2024

GlobeNewswire Inc.

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

GlobeNewswire Inc.

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

GlobeNewswire Inc.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

GlobeNewswire Inc.

Cytokinetics Inc Stock (CYTK) Financials Data

Cytokinetics Inc (CYTK) Revenue 2024

CYTK reported a revenue (TTM) of $7.53 million for the quarter ending December 31, 2023, a -92.04% decline year-over-year.

Cytokinetics Inc (CYTK) Net Income 2024

CYTK net income (TTM) was -$526.24 million for the quarter ending December 31, 2023, a -35.30% decrease year-over-year.

Cytokinetics Inc (CYTK) Cash Flow 2024

CYTK recorded a free cash flow (TTM) of -$415.75 million for the quarter ending December 31, 2023, a -33.75% decrease year-over-year.

Cytokinetics Inc (CYTK) Earnings per Share 2024

CYTK earnings per share (TTM) was -$5.45 for the quarter ending December 31, 2023, a -28.24% decline year-over-year.

Cytokinetics Inc Stock (CYTK) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
HENDERSON JOHN T	Director	Apr 25 '24	Sale	64.54	10,562	681,671	32,070
Malik Fady Ibraham	EVP Research & Development	Apr 09 '24	Option Exercise	6.67	28,605	190,795	171,172
Malik Fady Ibraham	EVP Research & Development	Apr 09 '24	Sale	74.31	32,605	2,422,918	138,567
Malik Fady Ibraham	EVP Research & Development	Mar 05 '24	Option Exercise	6.67	28,604	190,789	167,577
Malik Fady Ibraham	EVP Research & Development	Mar 05 '24	Sale	67.56	32,604	2,202,606	138,973
HENDERSON JOHN T	Director	Feb 14 '24	Option Exercise	4.44	5,000	22,200	47,632
HENDERSON JOHN T	Director	Feb 14 '24	Sale	76.48	5,000	382,400	42,632
Blum Robert I	President & CEO	Feb 13 '24	Option Exercise	6.67	12,500	83,375	454,297
Blum Robert I	President & CEO	Feb 13 '24	Sale	76.85	12,500	960,625	441,797
Malik Fady Ibraham	EVP Research & Development	Feb 06 '24	Option Exercise	6.67	28,605	190,795	175,578

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.